Apposite Capital seals first Healthcare III exit with CrestOptics sale to Evident
🇬🇧 English
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
🇸🇦 العربية
Apposite Capital تبيع CrestOptics إلى Evident | أول خروج من صندوق Healthcare III
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
ما كان نتيجة استثمار Apposite Capital في CrestOptics؟
استثمار Apposite Capital في عام 2021 ساعد في مضاعفة إيرادات CrestOptics ثلاث مرات، وإطلاق سبعة منتجات جديدة، وأتمتة العمليات رقميًا قبل بيعها إلى Evident كأول خروج من صندوق Healthcare III.
🇧🇩 বাংলা
Apposite Capital CrestOptics কে Evident-এ বিক্রি করেছে | Healthcare III ফonden প্রথম প্রস্থান
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Apposite Capital-এর CrestOptics-এ বিনিয়োগের ফলাফল কি ছিল?
Apposite Capital-এর ২০২১ সালের বিনিয়োগ CrestOptics-এর আয়কে ত্রিগুণ করতে সাহায্য করেছিল, সাতটি নতুন পণ্য চালু করেছিল এবং Evident-এ বিক্রি করার আগে অপারেশনগুলোকে ডিজিটালভাবে অটোমেট করত, যা এর Healthcare III ফonden প্রথম প্রস্থান।
🇩🇪 Deutsch
Apposite Capital verkauft CrestOptics an Evident | Erster Exit aus dem Healthcare III Fonds
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Was war das Ergebnis der Investition von Apposite Capital in CrestOptics?
Die Investition von Apposite Capital im Jahr 2021 half dabei, den Umsatz von CrestOptics zu verdreifachen, sieben neue Produkte auf den Markt zu bringen und den Betrieb zu digitalisieren, bevor das Unternehmen an Evident verkauft wurde – was den ersten Exit aus dem Healthcare III Fonds darstellt.
🇪🇸 Español
Apposite Capital vende CrestOptics a Evident | Primera salida del fondo Healthcare III
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
¿Cuál fue el resultado de la inversión de Apposite Capital en CrestOptics?
La inversión de Apposite Capital en 2021 ayudó a triplicar los ingresos de CrestOptics, lanzar siete nuevos productos y automatizar digitalmente las operaciones antes de vender a Evident como su primera salida del fondo Healthcare III.
🇫🇷 Français
Apposite Capital vend CrestOptics à Evident | Première sortie du fonds Healthcare III
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Quel a été le résultat de l'investissement d'Apposite Capital dans CrestOptics ?
L'investissement d'Apposite Capital en 2021 a aidé à tripler les revenus de CrestOptics, à lancer sept nouveaux produits et à automatiser numériquement les opérations avant la vente à Evident, marquant ainsi la première sortie du fonds Healthcare III.
🇮🇳 हिन्दी
Apposite Capital ने CrestOptics को Evident को बेचा | Healthcare III फंड का पहला निकास
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Apposite Capital के CrestOptics में निवेश का परिणाम क्या रहा?
Apposite Capital का 2021 का निवेश CrestOptics की आय को तीन गुना करने, सात नए उत्पाद लॉन्च करने और Evident को बेचने से पहले संचालन को डिजिटल रूप से स्वचालित करने में मदद की, जिससे यह उसके Healthcare III फंड का पहला निकास बन गया।
🇮🇩 Bahasa Indonesia
Apposite Capital menjual CrestOptics kepada Evident | Keluar pertama dari dana Healthcare III
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Apa hasil investasi Apposite Capital di CrestOptics?
Investasi Apposite Capital pada tahun 2021 membantu meningkatkan pendapatan CrestOptics tiga kali lipat, meluncurkan tujuh produk baru, dan mengotomatisasi operasi secara digital sebelum dijual kepada Evident sebagai keluar pertama dari dana Healthcare III.
🇯🇵 日本語
Apposite Capital が CrestOptics を Evident に売却 | Healthcare III ファンド初のエグジット
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Apposite Capital の CrestOptics への投資の結果は何でしたか？
Apposite Capital の 2021 年の投資により、CrestOptics の売上が 3 倍になり、7 つの新製品が発売され、Evident への売却前に運営がデジタル化され、これが Healthcare III ファンドの最初のエグジットとなりました。
🇧🇷 Português
Apposite Capital vende CrestOptics à Evident | Primeira saída do fundo Healthcare III
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Qual foi o resultado do investimento da Apposite Capital na CrestOptics?
O investimento da Apposite Capital em 2021 ajudou a triplicar as receitas da CrestOptics, lançar sete novos produtos e automatizar digitalmente as operações antes da venda para a Evident, marcando a primeira saída do fundo Healthcare III.
🇷🇺 Русский
Apposite Capital продала CrestOptics компании Evident | Первый выход из фонда Healthcare III
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Каков был результат инвестиций Apposite Capital в CrestOptics?
Инвестиция Apposite Capital в 2021 году помогла утроить доходы CrestOptics, запустить семь новых продуктов и автоматизировать операции в цифровом формате перед продажей компании Evident, что стало первым выходом из фонда Healthcare III.
🇨🇳 简体中文
Apposite Capital 将 CrestOptics 出售给 Evident | 首次 Healthcare III 基金退出
Apposite Capital has sold its portfolio company Crest Optics to Evident, marking the fund's first exit from its Apposite Healthcare III fund. The Rome-based optical imaging systems developer saw revenues triple after Apposite invested in 2021, launching seven new products and digitally automating operations during ownership. Crest Optics designs and manufactures spinning disk confocal and structured illumination microscopy modules, including the X-Light family and CICERO systems.
The acquisition formalizes and expands an existing partnership, broadening Evident's life science imaging portfolio and enhancing capabilities in high-speed, 3D imaging for research, pharma, and biotech applications. Crest Optics will maintain its Rome headquarters and continue partner relationships. Primo Capital was also a previous investor.
Leerink advised financially, Chiomenti legally, Deloitte conducted due diligence, and Roland Berger performed commercial analysis.
Apposite Capital 对 CrestOptics 的投资结果是什么？
Apposite Capital 的 2021 年投资帮助 CrestOptics 的收入翻三倍，推出七款新产品，并在出售给 Evident 前实现了运营的数字化自动化，标志着其 Healthcare III 基金的首次退出。